

38 (7)

J Rheumatol 2011;38:1223-1534  
<http://www.jrheum.org/content/38/7.citation>

1. Sign up for TOCs and other alerts  
<http://www.jrheum.org/alerts>
2. Information on Subscriptions  
<http://jrheum.com/faq>
3. Information on permissions/orders of reprints  
[http://jrheum.com/reprints\\_permissions](http://jrheum.com/reprints_permissions)

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.

# The Journal of Rheumatology

VOLUME 38: NO. 7

jrheum.org

JULY 2011

## Editorials

- All That Glitters Is Not Gold – Standardizing Diagnosis in Rheumatoid Arthritis Studies** *K.P. Liao, V. Bykerk* . . . . . 1223
- Who's Holding up the Queue? Delay in Treatment of Rheumatoid Arthritis** *J.E. Homik* . . . . . 1225
- Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment?** *E. Lubrano, S. D'Angelo, A. Spadaro, C. Palazzi, I. Olivieri* . . . . . 1228
- Should Clinicians Start Measuring Flow Mediated Dilation Response in Patients with Systemic Lupus Erythematosus?** *C.S. Lau* . . . . . 1231

## Review

- Challenges in Diagnosing Latent TB Infection in Patients Treated with TNF Antagonists** *E.C. Keystone, K.A. Papp, W. Wobeser* . . . . . 1234

## Articles

- Lymphotoxin- $\alpha$  252 A>G Polymorphism: A Link Between Disease Susceptibility and Dyslipidemia in RA?** *M.J. Santos, D. Fernandes, J. Caetano-Lopes, et al* . . . . . 1244
- Diagnostic Accuracy of ACR/EULAR 2010 Criteria for RA in a 2-Year Cohort** *S. Varache, D. Cornec, J. Morvan, et al* . . . . . 1250
- Incidence and Risk Factors for Serious Infection in Patients with RA Treated with TNF Inhibitors: A Report from the Registry of Japanese RA Patients for Longterm Safety** *Y. Komano, M. Tanaka, T. Nanki, et al, for the REAL Study Group* . . . . . 1258
- A Comparison Between IgG- and IgA-class Antibodies to CCP and to Modified Citrullinated Vimentin in Early RA and Very Early Arthritis** *A. Svård, A. Kastbom, M.K. Söderlin, Å. Reckner-Olsson, T. Skogh* . . . . . 1265
- Persistence with Anti-TNF Therapies in Patients with RA: Observations from the RADIUS Registry** *J.A. Markenson, A. Gibofsky, W.R. Palmer, et al* . . . . . 1273
- Time to Treatment for New Patients with RA in a Major Metropolitan City** *S. Jamal, S.M.H. Alibhai, E.M. Badley, C. Bombardier* . . . . . 1282
- Prognostic Indicators of Hospitalized Patients with SLE: A Large Retrospective Multicenter Study in China** *X. Feng, Y. Zou, W. Pan, et al* . . . . . 1289

- Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilation Is Significantly Reduced in Patients with SLE without Vascular Events: A Metaanalysis and Metaregression** *A. Mak, Y. Liu, R.C-M Ho* . . . . . 1296
- Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis** *K. Laskari, A.G. Tzioufas, A. Antoniou, H.M. Moutsopoulos* . . . . . 1304
- Quantitative Data for Care of Patients with SLE in Usual Clinical Settings: A Patient Multidimensional HAQ and Physician Estimate of Noninflammatory Symptoms** *A.D. Askanase, I. Castrejón, T. Pincus* . . . . . 1309
- Late-age Onset SSc** *R.L. Manno, F.M. Wigley, A.C. Gelber, L.K. Hummers* . . . . . 1317
- Expert Agreement on EULAR/EUSTAR Recommendations for the Management of SSc** *K.M. Walker, J. Pope, on behalf of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group* . . . . . 1326
- Malignancies in Italian Patients with SSc Positive for Anti-RNA Polymerase III Antibodies** *P. Airo, A. Ceribelli, I. Cavazzana, M. Taraborelli, S. Zingarelli, F. Franceschini* . . . . . 1329
- Rehabilitation Treatment in Patients with AS Stabilized with TNF Inhibitor Therapy. A Randomized Controlled Trial** *S. Masiero, L. Bonaldo, M. Pigatto, A. Lo Nigro, R. Ramonda, L. Punzi* . . . . . 1335
- The SPARCC Registry for SpA** *D.D. Gladman, P. Rahman, R.J. Cook, et al* . . . . . 1343
- Resolution of Inflammation Following Treatment of AS Is Associated with New Bone Formation** *S.J. Pedersen, P. Chiowchanwisawakit, R.G.W. Lambert, M. Østergaard, W.P. Maksymowych* . . . . . 1349
- Effectiveness and Safety of Etanercept in Patients with PsA in a Canadian Clinical Practice Setting: The REPARÉ Trial** *D.D. Gladman, C. Bombardier, C. Thorne, et al* . . . . . 1355
- High Prevalence of Subclinical Left Ventricular Dysfunction in Patients with PsA** *Q. Shang, L-S. Tam, G.W-K. Yip, et al* . . . . . 1363
- Prevalence of Thyroid Autoimmunity in Patients with SpA** *R. Peluso, G.A. Lupoli, A. Del Puente, et al* . . . . . 1371
- Candidate Genes in Patients with Autoinflammatory Syndrome Resembling TNF Receptor-associated Periodic Syndrome Without Mutations in the *TNFRSF1A* Gene** *S. Borghini, M. Fiore, M. Di Duca, et al* . . . . . 1378

 Free online via JRheum Full Release option

**Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors** *D.S. Goldfarb, P.A. MacDonald, B. Hunt, L. Gunawardhana* . . . . . 1385

**Consistency of Knee Pain and Risk of Knee Replacement: The Multicenter OA Study**  
*B.L. Wise, D.T. Felson, M. Clancy, et al.* . . . . . 1390

**Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons**  
*A.A. Khan, L.P. Rios, G.K.B. Sandor, et al.* . . . . . 1396

**Longterm Therapeutic Response to Milnacipran Treatment for FM. A European 1-Year Extension Study Following a 3-Month Study** *J.C. Branco, P. Cherin, A. Montagne, A. Bouroubi, on behalf of the Multinational Coordinator Study Group.* . . . . 1403

**Specialized Rheumatology Nurse Substitutes for Rheumatologists in the Diagnostic Process of FM: A Cost-Consequence Analysis and RCT**  
*M.E. Kroese, J.L. Severens, G.J. Schulpen, M.C. Bessems, F.J. Nijhuis, R.B. Landewé* . . . . . 1413

## Pediatric Rheumatology

**Heterotopic Ossification of the TMJ in JIA**  
*S. Ringold, M. Thapa, E.A. Shaw, C.A. Wallace* . . . . . 1423

**MBL Expression Genotype in Pediatric-onset SLE: Associations with Susceptibility to Renal Disease and Protection Against Infections** *Y-C. Tsai, K-W. Yeh, T-C. Yao, Y-L. Huang, M-L. Kuo, J-L. Huang.* . . . . . 1429

**Safety and Efficacy of Rituximab in Severe Juvenile DM: Results from 9 Patients from the French Autoimmunity and Rituximab Registry**  
*B. Bader-Meunier, H. Decaluwe, C. Barnerias, et al, for the Club Rhumatismes et Inflammation* . . . . . 1436

**Development of IBD in Patients with JIA Treated with Etanercept**  
*T.D. van Dijken, S.J. Vastert, V.M. Gerloni, et al.* . . . . . 1441

## Images in Rheumatology

**Fluorescence Optical Imaging of Juvenile Arthritis**  
*S.G. Werner, H-E. Langer, G. Horneff* . . . . . 1447

## OMERACT 10 10th International Consensus Conference on Outcome Measures in Rheumatology Kota Kinabalu, Borneo - May 4-8, 2010

Introduction . . . . . 1448

### Disease-specific Outcomes

**Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10** *J.A. Singh, W.J. Taylor, L.S. Simon, et al.* . . . . 1452

**Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities**  
*N. Dalbeth, F.M. McQueen, J.A. Singh, et al.* . . . . . 1458

**Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?**  
*L.K. Stamp, P.P. Khanna, N. Dalbeth, et al.* . . . . . 1462

**Bringing It All Together: A Novel Approach to the Development of Response Criteria for Chronic Gout Clinical Trials**  
*W.J. Taylor, J.A. Singh, K.G. Saag, et al.* . . . . . 1467

**Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda**  
*H. Direskeneli, S.Z. Aydin, T.A. Kermani, et al.* . . . . . 1471

**The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis**  
*P.A. Merkel, S.Z. Aydin, M. Boers, et al.* . . . . . 1480

**Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update**  
*P.J. Mease, D.J. Clauw, R. Christensen, et al, and the OMERACT Fibromyalgia Working Group.* . . . . . 1487

**Development of a Disease Severity and Responder Index for PsA — Report of the OMERACT 10 PsA SIG**  
*L.C. Coates, A. Mumtaz, P.S. Helliwell, et al.* . . . . . 1496

**Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10** *P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde.* . . . . . 1502

**Early Postoperative Mortality Following Joint Arthroplasty: A Systematic Review** *J.A. Singh, J. Kundukulam, D.L. Riddle, V. Strand, P. Tugwell* . . . . . 1507

**Developing Disease Activity and Response Criteria in CTD-related ILD** *L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group.* . . . . . 1514

## Correspondence

**Where in the World is Oral Triamcinolone?** *L. Roger.* . . . . 1519

**Reply** *R. Alten.* . . . . 1519

**Lupus Related Longitudinal Myelitis**  
*D.M. Wingerchuk, B.G. Weinshenker.* . . . . . 1520

**Reply** *P. Zotos.* . . . . 1521

**Coexistent WG and Goodpasture's Disease: What Is the Mechanism?** *J.I. Shin, S.J. Park, J.H. Kim.* . . . . . 1521

**Who Discovered the ESR?** *A. Grzybowski, J.J. Sak.* . . . . 1521

**Reply** *E.L. Matteson, C.S. Crowson.* . . . . 1523

## Letters

**Serum Levels of HMGB1 in Postmenopausal Patients with RA: Associations with Proinflammatory Cytokines, Acute-phase Reactants, and Clinical Disease Characteristics**  
*R. Pullerits, V. Urbonaviciute, R.E. Voll, H. Forsblad-D'Elia, H. Carlsten.* . . . . . 1523

**Acute Presentation of Tophaceous Myelopathy**  
*E. Levin, K. Hurth, R. Joshi, R. Brasington.* . . . . . 1525

**AS Refractory to TNF Blockade Responds to Tocilizumab**  
*J-D. Cohen, R. Ferreira, C. Jorgensen.* . . . . . 1527

**Positive C-ANCA with PR3 Specificity Glomerulonephritis in a Patient with Subacute Bacterial Endocarditis**  
*M. Uh, I.A. McCormick, J.T. Kelsall.* . . . . . 1528

**Primary Aldosteronism Simulating Polymyositis**  
*Y-C. Tang, S-K. Wang, W-L. Yuan.* . . . . . 1529

## Corrections

**Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial**  
*J.A. Singh, M.L. Mahowald, S. Noorbaloochi.* . . . . . 1534

**Anti-Fibrillar Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis** *S. Sharif, M.J. Fritzler, M.D. Mayes, et al.* . . 1534

**Meetings in Rheumatology** . . . . . xi